Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Das 13-Millionen-Unternehmen mit einer Monster-Entdeckung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
141 Leser
Artikel bewerten:
(0)

KDG Strengthens Market Leadership With Acquisition of Kennedy & Associates, Certified Public Accountants

Finanznachrichten News

Lehigh Valley based KDG Expands Service Offerings with Strategic Acquisition of Kennedy & Associates, Enhancing Expertise in Tax, Managed Accounting, and Outsourced CFO Services.

ALLENTOWN, PENNSYLVANIA / ACCESSWIRE / January 14, 2025 / The Kyle David Group, LLC (KDG), a prominent professional services firm specializing in technology, accounting, and strategy for small to mid-sized organizations, has successfully completed its asset acquisition of Kennedy & Associates, Certified Public Accountants. This strategic move, finalized in December, significantly enhances KDG's portfolio in small to midsized business tax, managed accounting, and fractional CFO services.

Kennedy & Associates, established in 2003, has built a solid reputation across New Jersey and beyond, serving a broad client base that spans the U.S. and extends to Mexico and Lebanon. Renowned for their professionalism and responsiveness, the firm has consistently met the diverse needs of its clients with a wide range of tailored accounting and tax solutions. Their extensive experience in real estate investing and peer recognition reflects their commitment to excellence in accounting practices. More information about their specialized services and client testimonials can be found on their website.

Kyle David, CEO of KDG, commented on the acquisition, stating, "The diligence process revealed much to admire about Kennedy & Associates-their business methods, their impressive client base, and their ability to deliver top-notch services. Their ethos aligns seamlessly with our strategic goals to enhance our managed accounting, tax, and fractional CFO services."

Jim Kennedy, Managing Member of Kennedy & Associates, remarked on the selection of KDG as the acquirer, "We evaluated numerous potential acquirers, and KDG distinguished itself not only through its conscientious approach and client-focused mindset but also because of its deep in-house expertise. Their demonstrated care and concern about every client, large or small complements their adherence to very high standards made them the ideal choice to ensure that our longstanding clients, many of whom have been with us for over two decades, continue to receive exceptional care"

This acquisition is a testament to KDG's ongoing commitment to leadership in providing comprehensive services in technology, accounting, and strategic management to small and mid-sized businesses.

About The Kyle David Group, LLC: The Kyle David Group, LLC (KDG) is a leading professional services firm that offers a robust blend of technology, accounting, and strategic solutions to small and mid-sized organizations. KDG is dedicated to driving business success and operational excellence for its clients.

About Kennedy & Associates: Kennedy & Associates has been a trusted provider of accounting services since its inception in 2003, with a diverse clientele spread across the United States and abroad. Their specialization in real estate investing and deep understanding of complex accounting challenges demonstrate their adaptability and commitment to client success.

Contact Information

Press Inquiries
info@kyledavidgroup.com
610-336-4822

.

SOURCE: KDG



View the original press release on accesswire.com

© 2025 ACCESSWIRE
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.